Siemens ADVIA Centaur BR assay Cat No. 03896216, SMN 10334837 (5-pack/250 tests) BR Assay for CA 27.29 The ADVIA Centaur® BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur®, ADVIA Centaur® XP, and ADVIA Centaur® XPT systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing for CA 27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.
Publicado el 12 de abril de 2017 · Inicio del retiro: 8 de marzo de 2017
Resumen
FDA registra el retiro Z-1748-2017 de dispositivos médicos de Clase II, publicado el 12 de abril de 2017 e iniciado el 8 de marzo de 2017. Empresa responsable: Siemens Healthcare Diagnostics, Inc; Estado: Finalizado; Cantidad reportada: 1900 kits; Lote: All lot codes. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Potential for the ADVIA Centaur Syphilis assay to interfere with the BR (CA 27.29) a assay on the ADVIA Centaur Systems
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Siemens Healthcare Diagnostics, Inc
- Distribuidor
- Worldwide Distribution - US (Nationwide) Internationally to Australia, Brazil, Canada, Columbia, Cyprus, Japan, Spain
- Lote
- All lot codes
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDASiemens ADVIA Centaur Folate 100 test kit-for IVD of folate in serum or red blood cells SMN:1031030829 de enero de 2020
- FDASiemensADVIA Centaur aTG (500 test kit) Siemens Material Number (SMN): 104923998 de mayo de 2019
- FDAAtellica IM aTG (500 test kit) Siemens Material Number (SMN): 109954628 de mayo de 2019
- FDASiemens Atellica IM aTG (100 test kit) Siemens Material Number (SMN): 109954618 de mayo de 2019
- FDABD Vacutainer Buffered Sodium Citrate: (9NC) Blood Collection Tubes, 4.5 mL, 13 x 75 mm, Mfd: Becton Dickinson12 de abril de 2017
- FDABrightView XCT model number 882482 BrightView and BrightView X are gamma cameras designed for single or dual12 de abril de 2017
Preguntas sobre este retiro
¿Siemens ADVIA Centaur BR assay Cat No. 03896216, SMN 10334837 (5-pack/250 tests) BR Assay for CA 27.29 The ADVIA Centaur® BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur®, ADVIA Centaur® XP, and ADVIA Centaur® XPT systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing for CA 27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1748-2017 el 12 de abril de 2017. Peligro reportado: Potential for the ADVIA Centaur Syphilis assay to interfere with the BR (CA 27.29) a assay on the ADVIA Centaur Systems
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter